Organon (OGN) shares were advancing nearly 1% in recent Thursday trading after the company posted its Q3 revenue ahead of consensus.
The company reported Q3 non-GAAP net income Thursday of $0.87 per diluted share, unchanged from a year earlier.
Analysts polled by Capital IQ expected $0.90.
Revenue for the quarter ended Sept. 30 rose to $1.58 billion from $1.52 billion a year earlier.
Analysts expected $1.56 billion.
For 2024, the women's health company is projecting revenue of $6.38 billion from $6.43 billion compared with its prior forecast range of $6.25 billion to $6.45 billion.
Analysts are looking for $6.39 billion.
Organon said its board declared a quarterly dividend of $0.28, payable Dec. 12 to stockholders of record on Nov. 12.
As of Sept. 30, Organon had cash and cash equivalents of $763 million.
Price: 18.10, Change: +0.17, Percent Change: +0.95
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.